1. Ambros, PF, Ambros, IM, Strehl, S, Bauer, S, Luegmayr, A, Kavar, H, Ladenstein, R, Fink, FM, Horcher, E & Printz, G et al (1995). Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?. Eur J Cancer 31A: 510–515.
2. Bell, GI, Yasuda, K, Kong, H, Law, SF, Raynor, K & Reisine, T (1995). Molecular biology of somatostatin receptors. Ciba Found Symp 190: 65–88.
3. Brodeur, GM (1998). Clinical and biological aspects of neuroblastoma. In:The Genetic Basis of Human Cancer, Vogelstein B, Kinzler KWMcGraw-Hill: New York 691–711.
4. Brodeur, GM, Pritchard, J, Berthold, F, Carlsen, NL, Castel, V, Castelberry, RP, De Bernardi, B, Evans, AE, Favrot, M & Hedborg, F et al (1993). Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466–1477.
5. Caron, H, van Sluis, P, van Roy, N, de Kraker, J, Speleman, F, Voute, PA, Westerveld, A, Slater, R & Veersteg, R (1994). Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. Am J Hum Genet 55: 341–347.